Insider · CIK 0001247681

LAWLIS V BRYAN

Reports to the SEC for 7 companies · NOVATO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001247681

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-05-21	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+180K sh	—	—	180,000
2025-05-09	GERNGERON CORPP Purchase	Director	PPurchase	+13.3K sh	$1.18	+$15.7K	13,300
2024-05-15	GERNGERON CORPM Exercise/Conversion	Director	MExercise/Conversion	+35K sh	$1.94	+$67.9K	35,000
2024-05-15	GERNGERON CORPS Sale	Director	SSale	−35K sh	$3.75	−$131K	0
2024-05-15	GERNGERON CORP · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−35K sh	—	—	0
2024-05-09	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+180K sh	—	—	180,000
2023-05-31	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+125K sh	—	—	125,000
2023-05-23	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+4,190 sh	—	—	33,140
2023-05-11	GERNGERON CORPM Exercise/Conversion	Director	MExercise/Conversion	+35K sh	$1.10	+$38.5K	35,000
2023-05-11	GERNGERON CORPS Sale	Director	SSale	−35K sh	$3.00	−$105K	0
2023-05-11	GERNGERON CORP · Stock Options (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−35K sh	—	—	0
2023-04-03	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+8,500 sh	$67.81	+$576K	37,450
2023-04-03	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−8,500 sh	$97.09	−$825K	28,950
2023-04-03	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to Buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−8,500 sh	—	—	0
2022-06-07	SYRESpyre Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+43K sh	—	—	43,000
2022-05-24	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+4,980 sh	—	—	28,950
2022-05-10	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+125K sh	—	—	125,000
2022-04-14	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+4,250 sh	$37.46	+$159K	28,220
2022-04-14	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−4,250 sh	$83.66	−$356K	23,970
2022-04-14	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−4,250 sh	—	—	0
2022-01-14	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+4,250 sh	$37.46	+$159K	28,220
2022-01-14	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−4,250 sh	$87.61	−$372K	23,970
2022-01-14	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−4,250 sh	—	—	4,250
2021-06-08	SYRESpyre Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2021-05-25	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+5,120 sh	—	—	23,970
2021-05-11	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+83K sh	—	—	83,000
2021-04-15	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+7,500 sh	$26.49	+$199K	26,350
2021-04-15	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−7,500 sh	$76.90	−$577K	18,850
2021-04-15	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−7,500 sh	—	—	0
2021-02-16	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+7,500 sh	$26.49	+$199K	26,350
2021-02-16	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−7,500 sh	$87.41	−$656K	18,850
2021-02-16	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−7,500 sh	—	—	7,500
2021-01-11	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2020-06-08	SYRESpyre Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+28.1K sh	—	—	28,100
2020-06-05	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−4,430 sh	$107.46	−$476K	18,850
2020-06-05	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+83K sh	—	—	83,000
2020-05-27	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+4,300 sh	—	—	23,280
2020-03-17	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	$21.51	+$80.7K	22,730
2020-03-17	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−3,750 sh	$75.39	−$283K	18,980
2020-03-17	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−3,750 sh	—	—	0
2020-03-16	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−4,610 sh	$76.52	−$353K	18,980
2020-01-10	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-12-17	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	$21.51	+$80.7K	27,340
2019-12-17	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−3,750 sh	$83.36	−$313K	23,590
2019-12-17	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−3,750 sh	—	—	3,750
2019-09-17	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	$21.51	+$80.7K	27,340
2019-09-17	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−3,750 sh	$74.47	−$279K	23,590
2019-09-17	BMRNBIOMARIN PHARMACEUTICAL INC · Stock Option (Right to buy Common Stock)M Exercise/Conversion	Director	MExercise/Conversion	−3,750 sh	—	—	7,500
2019-06-17	BMRNBIOMARIN PHARMACEUTICAL INCM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	$21.51	+$80.7K	27,340
2019-06-17	BMRNBIOMARIN PHARMACEUTICAL INCS Sale	Director	SSale	−3,750 sh	$81.08	−$304K	23,590

Recent filings

Accepted (ET)
May 224
LAWLIS V BRYAN0000886744-25-000025
SEC(opens sec.gov)
May 134
LAWLIS V BRYAN0000886744-25-000013
SEC(opens sec.gov)
May 174
LAWLIS V BRYAN0000950170-24-061615
SEC(opens sec.gov)
May 104
LAWLIS V BRYAN0000950170-24-057795
SEC(opens sec.gov)
Jun 24
LAWLIS V BRYAN0001062993-23-012815
SEC(opens sec.gov)
May 244
LAWLIS V BRYAN0001209191-23-031973
SEC(opens sec.gov)
May 114
LAWLIS V BRYAN0001062993-23-010852
SEC(opens sec.gov)
Apr 44
LAWLIS V BRYAN0001209191-23-023062
SEC(opens sec.gov)
Jun 94
LAWLIS V BRYAN0001209191-22-035685
SEC(opens sec.gov)
May 264
LAWLIS V BRYAN0001567619-22-011796
SEC(opens sec.gov)
May 114
LAWLIS V BRYAN0001062993-22-012155
SEC(opens sec.gov)
Apr 184
LAWLIS V BRYAN0001567619-22-008633
SEC(opens sec.gov)

Companies

Address

C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE

NOVATO, CA, 94949